This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

ICD-10 F02.0 — Dementia in Pick disease (G31.00†) Special Copayment Reduction: V800

Dementia in Pick disease, G31.00†픽병에서의 치매

Synonyms: Pick disease dementia, frontotemporal dementia (Pick type), Pick dementia, FTD-Pick type

ICD-10 dual coding guide
F02.0 is an asterisk (*) code describing the mental and behavioral symptoms of dementia accompanying Pick disease, and must always be used together with the dagger (†) code G31.00 (Pick disease), which indicates the underlying neuropathology. On claims, enter G31.00† F02.0* in this order; the principal diagnosis is G31.00†. By entering both codes, both the neurological cause (G31.00) and the psychiatric syndrome (F02.0) are reflected at the same time.
Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Pick disease was first described in 1892, when the Czech neuropsychiatrist Arnold Pick reported the case of a 71-year-old man with language impairment and personality change together with focal atrophy of the left frontal and temporal lobes. In this case Pick emphasized the association between circumscribed cortical atrophy and the clinical syndrome, but the pathological mechanism was not clearly elucidated at the time. In 1911, Alois Alzheimer discovered distinctive intraneuronal inclusions positive on silver staining (Pick bodies) and ballooned neurons (Pick cells) in atrophic frontotemporal brains, and Pick disease began to be recognized as an independent pathological entity.

Until the mid-20th century, Pick disease was grouped with Alzheimer disease in the category of "presenile dementia." In the 1980s, the Lund group in Sweden and the Manchester group in the UK established the concept of frontotemporal dementia (FTD) through systematic clinicopathological studies, and clinical diagnosis was systematized with the publication of the Lund-Manchester criteria in 1994. Subsequently, in 1998, MAPT gene mutations were linked to tauopathy, and in 2006 the TDP-43 protein was shown to be a major component of FTLD pathology, leading to reclassification at the molecular pathology level. Currently in ICD-10, F02.0 (dementia in Pick disease) and G31.00 (Pick disease) are operated under a dual coding system, and DSM-5 classifies it as the frontotemporal variant of major neurocognitive disorder.

2. Causes

Pick disease is a pathological subtype of frontotemporal lobar degeneration (FTLD), in which abnormal accumulation of hyperphosphorylated tau protein within neurons is the key pathogenesis. Normal tau protein is a microtubule-associated protein essential for microtubule stabilization and axonal transport, but hyperphosphorylated tau detaches from microtubules and aggregates into insoluble fibrils in the cytoplasm to form Pick bodies. Pick bodies are intraneuronal inclusions in which the 3-repeat tau (3R tau) isoform predominates, distinguishing them from the mixed 3R/4R pathology seen in Alzheimer disease.

In FTLD-TDP, another major subtype of frontotemporal pathology, TAR DNA-binding protein 43 (TDP-43) translocates from the nucleus to the cytoplasm and forms aggregates, and in FTLD-FUS the FUS protein is involved by a similar mechanism. A considerable number of cases presenting clinically as behavioral variant frontotemporal dementia (bvFTD) have FTLD-TDP pathology, so the term "Pick disease" is narrowly limited to tau-positive Pick body pathology (FTLD-tau, Pick type), but in clinical and historical contexts it is also used to refer to bvFTD as a whole. Because clinical phenotype, genetic associations, and prognosis differ by underlying pathology type, biomarker-based classification is clinically important.

Sporadic cases are more common, but in familial cases abnormalities of the MAPT, GRN, and C9orf72 genes have been identified as the main causes. The role of environmental and toxic factors is not yet clear, but a history of head trauma has been proposed as a risk factor in some studies.

3. Genetics

The genetic causes of Pick disease and frontotemporal dementia are summarized in three major genes. First, pathogenic variants in the MAPT (Microtubule Associated Protein Tau) gene (17q21.31) are a direct cause of FTLD-tau, and dozens of missense and splicing variants such as P301L, R406W, and V337M have been reported. MAPT variant carriers show near-complete penetrance, and the mean age of onset is in the 40s–60s.

Second, loss-of-function variants in the GRN (Progranulin) gene (17q21.32) cause FTLD-TDP (type A), and haploinsufficiency reduces the progranulin protein and promotes neurodegeneration. GRN variant carriers show a pattern on brain PET suggesting TDP-43 pathology rather than tau. Third, a GGGGCC hexanucleotide repeat expansion in the C9orf72 gene (9p21.2) is the most common single genetic cause of FTD-ALS, the overlapping phenotype of FTD with amyotrophic lateral sclerosis (ALS), as well as of FTD, and FTLD-TDP type B findings meeting the pathological criteria for Pick disease have been reported in some cases.

Other rare causative genes include TARDBP (encoding the TDP-43 protein), FUS, CHMP2B, VCP, SQSTM1, and TBK1. When an autosomal dominant inheritance pattern across 3 generations is confirmed on family history, genetic panel testing is recommended; identification of a MAPT variant raises the likelihood of FTLD-tau (Pick body or corticobasal type), and measurement of blood progranulin and C9orf72 repeat testing are performed stepwise.

4. General epidemiology

Frontotemporal dementia (FTD), including Pick disease, is the second most common cause of early-onset dementia under age 65 after Alzheimer disease, and in the 45–64 age group its prevalence is similar to that of Alzheimer disease or, in some reports, higher. According to European and North American studies, the prevalence of FTD at ages 45–64 is estimated at about 15–22 per 100,000 population and the incidence at 2.7–4.1 per year. Domestic data are limited, but in a Korean study using Health Insurance Review & Assessment Service (HIRA) data, the prevalence of frontotemporal dementia has shown a continuing upward trend and accounts for about 2–5% of all dementia patients aged 65 and older.

Age of onset is usually 45–65 years; onset after 65 is possible but less frequent. Sex differences are not significant in most studies or tend to be slightly higher in men. Pathologically confirmed Pick disease (FTLD-tau, Pick type) accounts for about 20–30% of all FTD, with the remainder made up of FTLD-TDP (about 40–50%), FTLD-FUS (about 5%), and other or unclassified pathologies. Familial FTD accounts for 30–40% of the total, of which MAPT variants are estimated at 15–20%, GRN variants at 5–10%, and C9orf72 repeat expansions at 10–15%.

Comorbid conditions include parkinsonian syndromes, amyotrophic lateral sclerosis (FTD-ALS overlap), corticobasal syndrome (CBS), and progressive supranuclear palsy (PSP); FTD-ALS overlap cases are strongly associated with C9orf72 repeat expansion. The median disease duration is about 6–11 years from the time of diagnosis, but the total period from symptom onset to death varies widely, from 2 to 20 years.

5. Pathophysiology

The core pathology of Pick disease is 3-repeat tauopathy (3R tauopathy); whereas the 3R:4R tau ratio is normally maintained at about 1:1 in the adult brain, 3R tau is overwhelmingly predominant in the Pick disease brain. Dysregulation of alternative splicing of exon 10 of MAPT pre-mRNA is proposed as the main mechanism for overproduction of the 3R isoform. Hyperphosphorylated 3R tau detaches from microtubules and aggregates in the cell body and proximal dendrites to form spherical Pick bodies, which are strongly positive on Gallyas silver staining and tau immunohistochemistry.

Neurons in layers 3–5 of the frontal and temporal cortex are selectively involved, and ballooned neurons (Pick cells) show cell body swelling and loss of Nissl substance. Neuroinflammatory mechanisms are also important, and microglial activation and reactive astrocytosis are observed around lesions. Recent studies show that tau oligomers are more neurotoxic than monomers or mature fibrils, and evidence is accumulating that the lesion spreads to adjacent neural networks through a prion-like propagation mechanism of tau.

In FTLD-TDP, TDP-43 translocates from the nucleus to the cytoplasm and forms ubiquitin-positive, p62-positive inclusions. Loss of the normal functions of TDP-43 (RNA processing, splicing, transcription regulation) disrupts neuronal homeostasis. In FUS pathology as well, impaired nucleocytoplasmic transport of the FUS protein occurs similarly. Frontal lobe atrophy is directly linked to impairment of inhibitory control, working memory, social cognition, and decision-making, while temporal lobe atrophy is associated with impairment of semantic memory and language processing.

6. Symptoms

Dementia in Pick disease (F02.0) most commonly presents clinically as the phenotype of behavioral variant frontotemporal dementia (bvFTD), in which personality change and abnormal social behavior come to the fore early on rather than memory impairment. Disinhibition, apathy, reduced empathy, compulsive or repetitive behavior, changes in eating habits (overeating, fixation on particular foods), and oral behaviors (hyperorality) are the typical early symptoms.

Disinhibition symptoms may include speech and behavior inappropriate to the social context, sexually inappropriate behavior, impulsive acts (unplanned purchases, gambling), and legal problems (theft, traffic violations). Apathy resembles depression in outward appearance, but is characterized by a global decrease in motivation, spontaneity, and emotional responsiveness without sadness or dysphoria. Reduced empathy and emotional blunting are the main reasons families say the patient's personality has changed completely.

Language symptoms include reduced speech output, use of stereotyped language, echolalia, and perseveration, and with progression it may reach mutism. In contrast, spatial orientation and memory are relatively preserved early on, which clinically distinguishes it from Alzheimer disease, which begins with memory decline. In the cognitive domain, executive function, working memory, attention, and abstract thinking are selectively impaired, while memory and visuospatial function may be relatively preserved until the late stage.

As for motor symptoms, with disease progression parkinsonian syndromes (muscle rigidity, bradykinesia), nystagmus or oculomotor disorders, dysphagia, and incontinence may appear, and in some cases symptoms of motor neuron disease (MND) accompany.

7. Signs

On neurological examination there are often no clear focal signs early on, but primitive reflexes reflecting frontal lobe dysfunction may appear early. The grasp reflex, sucking reflex, rooting reflex, and snout reflex are typical, and suggest loss of frontal inhibitory function. Imitation behavior and utilization behavior are classic signs of damage to the supplementary motor area and frontal cortex.

On psychiatric examination, lack of insight is marked, and in most cases the patient does not recognize his or her abnormal behavior. Reduced facial expression, reduced spontaneous speech, and abnormal eye contact are observed. On neuropsychological testing, marked decline is seen on the Wisconsin Card Sorting Test (WCST), Trail Making Test B, Stroop color-word test, and verbal fluency tests, whereas memory tests (delayed recall) are relatively preserved early on.

Motor system signs may include parkinsonian findings (rigidity, bradykinesia, postural instability), corticobasal syndrome (alien limb, myoclonus, apraxia), and progressive supranuclear palsy features (vertical supranuclear palsy, axial rigidity), which are related to the underlying pathology type. In the late stage, dysphagia, dysarthria, urinary incontinence, and limb rigidity progress to a state of dependence.

8. Screening

For screening of frontotemporal dementia, a tool that intensively evaluates frontal lobe function is essential. The Frontal Assessment Battery (FAB) evaluates 6 items — conceptualization, flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy — on an 18-point scale, and a total score of 12 or below suggests frontal lobe dysfunction. The Mini-Mental State Examination (MMSE) and MoCA do not sufficiently reflect frontal lobe function and may miss early bvFTD, so using them alone is inappropriate.

The Neuropsychiatric Inventory (NPI) is widely used to screen for behavioral symptoms, and scores on the disinhibition, apathy, and aberrant behavior items are significantly higher than in Alzheimer disease. The Cambridge Behavioural Inventory-Revised (CBI-R) and the Frontal Systems Behaviour Scale (FrSBe) are assessment tools specific to frontotemporal behavioral symptoms, administered in a caregiver-report format. Under the diagnostic criteria for behavioral variant FTD (FTDC, 2011), possible bvFTD can be diagnosed when 3 or more of the 6 core features (disinhibition, apathy/reduced motivation, reduced empathy, stereotyped-compulsive behavior, hyperorality/changes in eating habits, abnormal neuropsychological profile) are present.

Brain MRI is the first-line imaging test for confirming the presence of focal atrophy of the frontal and anterior temporal lobes, and FDG-PET shows the pattern of hypometabolism in the frontal and anterior temporal lobes. CSF biomarkers (total tau, phosphorylated tau, Aβ42) are useful for excluding Alzheimer disease; in Pick disease, CSF Aβ42 is normal and the tau/Aβ42 ratio is low, differentiating it from Alzheimer disease.

9. Diagnosis

Clinical diagnosis of dementia in Pick disease (F02.0) is based on the 2011 International Behavioural Variant FTD Criteria Consortium (FTDC) criteria. Possible bvFTD is diagnosed when 3 or more of the 6 core features are met together with clinical evidence of a neurodegenerative disease, and probable bvFTD applies when, in addition to the possible criteria, atrophy, hypometabolism, or hypoperfusion of the frontal or anterior temporal lobes is confirmed on imaging. Definite bvFTD requires histopathology or identification of a known pathogenic variant.

On brain MRI, asymmetric or symmetric atrophy of the frontal and anterior temporal lobes is characteristic, and subcortical white matter signal changes on FLAIR are less common than in Alzheimer disease. FDG-PET visualizes a fronto-temporal hypometabolism pattern, which is distinguished from the parieto-temporal hypometabolism mainly observed in Alzheimer disease. Note that tau PET (18F-flortaucipir) shows high affinity for the mixed 3R/4R tau of Alzheimer disease, but has limited binding to the 3R tau of Pick disease, so it may be negative or show only weak binding. Next-generation tau PET tracers (18F-PI-2620, etc.) are under study for detection of FTLD-tau.

On CSF biomarkers, Pick disease shows normal Aβ42, normal or mildly elevated total tau, and normal or mildly elevated phosphorylated tau (p-tau181, p-tau217), distinguishing it from Alzheimer disease, which shows decreased Aβ42 and markedly elevated p-tau. Among plasma biomarkers, plasma GFAP and NfL (neurofilament light chain) are significantly elevated, and NfL in particular increases in proportion to the rate of neurodegeneration. When a GRN variant is suspected, measurement of plasma progranulin concentration (reduced to 30–50% of normal) has diagnostic value.

Genetic testing is performed first in patients with a family history, using an FTD gene panel that includes C9orf72 repeat expansion (repeat-primed PCR), MAPT sequencing, and GRN sequencing. On histopathology, Pick bodies are strongly positive on tau immunohistochemistry (clones AT8, PHF-1) and Gallyas silver staining, and are confirmed with a 3R tau-selective antibody (clone RD3).

10. Treatment

To date, no disease-modifying treatment for Pick disease and frontotemporal dementia has been approved, and treatment consists mainly of symptomatic therapy aimed at symptom relief and maintenance of function. Unlike in Alzheimer disease, cholinesterase inhibitors (AChEI) have been reported to be ineffective in FTD or even to worsen behavioral symptoms, so they are not recommended in principle for pure FTD.

For management of behavioral symptoms, selective serotonin reuptake inhibitors (SSRIs) (sertraline, fluvoxamine, paroxetine) have shown beneficial effects on disinhibition, impulsivity, compulsive behavior, and increased appetite in some randomized controlled trials, but the level of evidence is limited. Low-dose atypical antipsychotics (quetiapine, risperidone) are used for severe disinhibition or aggression, but must be used cautiously at the minimum dose, considering the risk of worsening parkinsonism and cardiovascular adverse effects. Randomized controlled trials of memantine in FTD showed no significant effect, but some clinicians use it on a trial basis in moderate or more advanced cases.

Non-pharmacological treatment includes maintaining a structured daily routine, behavioral therapy, environmental modification (dietary restriction, controlling access to food), occupational therapy, speech therapy, and physical therapy, and when language symptoms are present, introduction of augmentative and alternative communication (AAC) tools is considered. Family education and support programs play a key role in reducing caregiver burden and maintaining the patient's safe life at home.

Disease-modifying treatment research in clinical trial stages includes anti-tau immunotherapy, tau aggregation inhibitors, microtubule stabilizers, and progranulin replacement therapy in GRN variant carriers (ILB-202: recombinant progranulin).

11. Prognosis

Dementia in Pick disease generally has a poor prognosis, with a median survival from diagnosis to death of about 6–9 years. However, counted from symptom onset, the total duration varies greatly, from 2 to 20 years. Prognosis varies by underlying pathology type, age of onset, genetic background, and comorbid conditions, and MAPT variant carriers and C9orf72 repeat expansion carriers generally show rapid progression. FTD-ALS overlap cases have a worse prognosis than ALS alone, and respiratory failure is the main cause of death.

The clinical course can be divided into three stages. Early on, personality change and behavioral abnormalities predominate while daily functioning is relatively maintained; in the middle stage, loss of decision-making capacity, decline in language function, and appearance of motor symptoms sharply increase dependence on caregivers. In the late stage, complications such as akinetic mutism, dysphagia, pressure ulcers, and urinary tract infections accumulate, and institutionalization becomes necessary.

For tracking functional level, the Clinical Dementia Rating-Frontotemporal Lobar Degeneration (CDR+NACC FTLD) rating scale and the Frontotemporal Dementia Rating Scale (FRS) are used. The level of plasma NfL elevation is used as a surrogate marker of the rate of neurodegeneration, and a high baseline NfL level is associated with rapid progression. Advance care planning, completion of life-sustaining treatment plan forms, and linkage to hospice should be discussed by the multidisciplinary team with the family early after diagnosis.

12. Prevention

To date, there is no established primary prevention for Pick disease and frontotemporal dementia. In familial FTD, once the causative variant is identified in the proband, genetic counseling and presymptomatic genetic testing can be offered to adult family members, and joint counseling with a mental health professional is recommended in that case. A prospective cohort study registering and following MAPT, GRN, and C9orf72 variant carriers (GENFI: Genetic FTD Initiative) is under way, and prodromal-stage biomarkers and models for predicting the time of symptom onset are being developed through it.

Education level, intellectual activity, and social participation, which are associated with increased cognitive reserve, have well-known protective effects in Alzheimer disease, but their role in FTD is still unclear. Reducing the risk of head trauma and managing cardiovascular risk factors are recommended for maintaining general brain health. A preventive intervention clinical trial (ALLFTD: Advancing Research and Treatment for Frontotemporal Lobar Degeneration) is under way in GRN variant carriers through administration of solanezumab or recombinant progranulin.

Regular mental health support for caregivers and family, linkage to community Dementia Relief Centers, and legal and financial advance preparation (appointment of a guardian, asset management planning) are preventive measures that the multidisciplinary team should proactively guide from immediately after diagnosis.

13. References